152 related articles for article (PubMed ID: 32957879)
1. In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors.
Arya R; Paliwal S; Gupta SP; Sharma S; Madan K; Mishra A; Verma K; Chauhan N
Comb Chem High Throughput Screen; 2021; 24(5):729-736. PubMed ID: 32957879
[TBL] [Abstract][Full Text] [Related]
2. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
[TBL] [Abstract][Full Text] [Related]
3. Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease.
Ribaudo G; Coghi P; Zanforlin E; Law BYK; Wu YYJ; Han Y; Qiu AC; Qu YQ; Zagotto G; Wong VKW
Bioorg Chem; 2019 Jun; 87():474-483. PubMed ID: 30927588
[TBL] [Abstract][Full Text] [Related]
4. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
Razzaghi-Asl N; Karimi A; Ebadi A
Comput Biol Chem; 2018 Dec; 77():307-317. PubMed ID: 30445338
[TBL] [Abstract][Full Text] [Related]
5. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 Inhibitor: Plausible Lead for Alzheimer's Disease.
Jain P; Wadhwa PK; Jadhav HR
Med Chem; 2021; 17(10):1194-1206. PubMed ID: 33349218
[TBL] [Abstract][Full Text] [Related]
9. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
[TBL] [Abstract][Full Text] [Related]
10. Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents.
Gupta SP; Patil VM
Curr Top Med Chem; 2020; 20(13):1195-1213. PubMed ID: 32297584
[TBL] [Abstract][Full Text] [Related]
11. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
12. BACE inhibitors as potential therapeutics for Alzheimer's disease.
Evin G; Kenche VB
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):188-99. PubMed ID: 18221231
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase.
Palakurti R; Vadrevu R
Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354
[TBL] [Abstract][Full Text] [Related]
14. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
Kumar A; Srivastava G; Sharma A
Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
[TBL] [Abstract][Full Text] [Related]
15. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay.
Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y
Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408
[TBL] [Abstract][Full Text] [Related]
16. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
[TBL] [Abstract][Full Text] [Related]
17. In Silico Inhibition of BACE-1 by Selective Phytochemicals as Novel Potential Inhibitors: Molecular Docking and DFT Studies.
Arif N; Subhani A; Hussain W; Rasool N
Curr Drug Discov Technol; 2020; 17(3):397-411. PubMed ID: 30767744
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
19. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Pont C; Ginex T; Griñán-Ferré C; Scheiner M; Mattellone A; Martínez N; Arce EM; Soriano-Fernández Y; Naldi M; De Simone A; Barenys M; Gómez-Catalán J; Pérez B; Sabate R; Andrisano V; Loza MI; Brea J; Bartolini M; Bolognesi ML; Decker M; Pallàs M; Luque FJ; Muñoz-Torrero D
Eur J Med Chem; 2021 Dec; 225():113779. PubMed ID: 34418785
[TBL] [Abstract][Full Text] [Related]
20. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease.
Hossain T; Mukherjee A; Saha A
Mol Biosyst; 2015 Feb; 11(2):549-57. PubMed ID: 25435329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
